Niagen Bioscience, Inc.
NAGE
$6.49
$0.091.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.99M | 31.12M | 30.48M | 29.13M | 25.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.99M | 31.12M | 30.48M | 29.13M | 25.58M |
| Cost of Revenue | 12.06M | 10.89M | 11.15M | 10.93M | 9.34M |
| Gross Profit | 21.93M | 20.23M | 19.33M | 18.20M | 16.24M |
| SG&A Expenses | 15.90M | 15.47M | 13.30M | 9.77M | 13.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.75M | 27.93M | 25.71M | 22.01M | 23.98M |
| Operating Income | 4.24M | 3.19M | 4.77M | 7.11M | 1.60M |
| Income Before Tax | 4.80M | 3.74M | 5.23M | 7.48M | 1.88M |
| Income Tax Expenses | 222.00K | 128.00K | 168.00K | 305.00K | -- |
| Earnings from Continuing Operations | 4.58M | 3.61M | 5.06M | 7.18M | 1.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.58M | 3.61M | 5.06M | 7.18M | 1.88M |
| EBIT | 4.24M | 3.19M | 4.77M | 7.11M | 1.60M |
| EBITDA | 4.43M | 3.38M | 4.97M | 7.30M | 1.80M |
| EPS Basic | 0.06 | 0.05 | 0.07 | 0.09 | 0.02 |
| Normalized Basic EPS | 0.04 | 0.03 | 0.04 | 0.06 | 0.02 |
| EPS Diluted | 0.05 | 0.04 | 0.06 | 0.09 | 0.02 |
| Normalized Diluted EPS | 0.03 | 0.03 | 0.04 | 0.06 | 0.02 |
| Average Basic Shares Outstanding | 79.78M | 79.25M | 77.81M | 76.95M | 75.97M |
| Average Diluted Shares Outstanding | 86.62M | 86.24M | 83.23M | 81.68M | 77.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |